The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of YRCW, PRGO, AVEO and CVS
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
YRC Worldwide Inc. (NASDAQGS: YRCW) Class Period: March 10, 2014 to December 14, 2018 Lead Plaintiff Deadline: March 4, 2019
The complaint alleges that throughout the class period YRC Worldwide Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) from 2005 to at least 2013, YRC’s units systematically overcharged the federal government for freight carrier services; (2) this alleged misconduct caused the Department of Defense to overpay by millions of dollars for shipments that were lighter, and thus cheaper, than the weights for which the government was charged; (3) consequently, this alleged misconduct would subject YRC to enhanced government scrutiny and liabilities, including potentially owing treble damages under the False Claims Act; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Get additional information about the YRCW lawsuit: http://www.kleinstocklaw.com/pslra-1/yrc-worldwide-inc-loss-submission-form?wire=3
Perrigo Company plc (NYSE: PRGO) Class Period: November 8, 2018 to December 20, 2018 Lead Plaintiff Deadline: March 4, 2019
During the Class Period, and unbeknownst to investors, Perrigo misled investors by way of an SEC filing on November 8, 2018. On that date, Perrigo disclosed the existence of an audit finding letter from the Irish tax authorities without disclosing material details associated with the letter.
Get additional information about the PRGO lawsuit: http://www.kleinstocklaw.com/pslra-1/perrigo-company-plc-loss-submission-form?wire=3
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) Class Period: August 4, 2016 to January 31, 2019 Lead Plaintiff Deadline: April 26, 2019
The lawsuit alleges that throughout the class period, AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.
Get additional information about the AVEO lawsuit: http://www.kleinstocklaw.com/pslra-1/aveo-pharmaceuticals-inc-loss-submission-form?wire=3
CVS Health Corporation (NYSE: CVS) Class Period: May 21, 2015 to February 20, 2019 Lead Plaintiff Deadline: April 26, 2019
According to the complaint, CVS Health Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) CVS Health’s financial condition and expected earnings were deteriorating as a result of rising costs and poor results associated with the Omnicare Acquisition; and (ii) as a result, CVS Health’s public statements were materially false and misleading at all relevant times.
Get additional information about the CVS lawsuit: http://www.kleinstocklaw.com/pslra-1/cvs-health-corporation-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.